argatroban + enoxaparin

argatroban + enoxaparin refers to a therapeutic strategy being investigated in a Phase 2 clinical trial by University Hospital Ostrava for the prevention of thrombosis in patients requiring extracorporeal membrane oxygenation (ECMO). Argatroban is a synthetic direct thrombin inhibitor that binds reversibly to the active site of thrombin, providing anticoagulation without the need for antithrombin III. Enoxaparin is a low-molecular-weight heparin (LMWH) that acts primarily by binding to and accelerating the activity of antithrombin III, which in turn inhibits coagulation factors Xa and IIa (thrombin). The trial evaluates low-dose versus standard-dose regimens of these agents, controlled by anti-IIa and anti-Xa levels respectively, to optimize the balance between preventing clot formation and minimizing bleeding risks in critically ill patients with heart or pulmonary failure.

Other names

Low-dose Versus Standard-dose Anticoagulation With Argatroban and Enoxaparin During Extracorporeal Membrane Oxygenation Controlled by Anti-IIa and Anti-Xa